|
000
| 02170nam 2200373zi 4500 |
|---|
| 001 | 9.892881 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20231215145919 |
|---|
| 006 | m o d f |
|---|
| 007 | cr |n||||||||| |
|---|
| 008 | 201027t20202020onc ob f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH113-30/2020-4E-PDF |
|---|
| 245 | 00|aSpecial reviews of pymetrozine and its associated end-use products : |bconsultation document. |
|---|
| 264 | 1|aOttawa, Ontario : |bPest Management Regulatory Agency, Health Canada, |c2020. |
|---|
| 264 | 4|c©2020 |
|---|
| 300 | |a1 online resource (33 pages). |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 490 | 1 |aProposed special review decision, |x2561-6366 ; |vPSRD2020-04 |
|---|
| 500 | |aIssued also in French under title: Examens spéciaux de la pymétrozine et des préparations commerciales connexes : document de consultation. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"15 October 2020." |
|---|
| 504 | |aIncludes bibliographical references (pages 27-33). |
|---|
| 520 | |a"Pursuant to subsection 17(2) of the Pest Control Products Act (PCPA), Health Canada’s Pest Management Regulatory Agency (PMRA) initiated a special review of pymetrozine in 2015 (Canada, 2015) based on the 2014 Norway regulatory decision to prohibit all uses of pymetrozine (Rotterdam Convention 2014). The aspect of concern for the special review under subsection 17(2) is relevant to human health (potential carcionogenicity of pymetrozine)"--Introduction, page 1. |
|---|
| 650 | 0|aInsecticides|xCertification|zCanada. |
|---|
| 650 | 0|aInsecticides|xToxicology. |
|---|
| 650 | 0|aInsecticides|xEnvironmental aspects. |
|---|
| 710 | 1 |aCanada. |bPest Management Regulatory Agency, |eissuing body. |
|---|
| 775 | 08|tExamens spéciaux de la pymétrozine et des préparations commerciales connexes : |w(CaOODSP)9.892882 |
|---|
| 830 | #0|aProposed special review decision (Canada. Pest Management Regulatory Agency)|x2561-6366 ; |vPSRD2020-04.|w(CaOODSP)9.853990 |
|---|
| 856 | 40|qPDF|s358 KB|uhttps://publications.gc.ca/collections/collection_2020/sc-hc/h113-30/H113-30-2020-4-eng.pdf|zReport |
|---|